Vigil Neuroscience (NASDAQ:VIGL) Given New $24.00 Price Target at Wedbush

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) had its price target raised by stock analysts at Wedbush from $23.00 to $24.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an "outperform" rating on the stock.

VIGL has been the topic of several other reports. Guggenheim cut their price objective on shares of Vigil Neuroscience from $17.00 to $16.00 and set a "buy" rating on the stock in a report on Wednesday, August 14th. HC Wainwright reaffirmed a "buy" rating and set a $17.00 price target on shares of Vigil Neuroscience in a research note on Friday. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, Vigil Neuroscience has an average rating of "Moderate Buy" and a consensus target price of $16.80.

Vigil Neuroscience Price Performance

Shares of VIGL remained flat at $3.57 on Friday. 47,893 shares of the company traded hands, compared to its average volume of 236,640. Vigil Neuroscience has a fifty-two week low of $2.47 and a fifty-two week high of $6.98. The firm has a 50-day moving average price of $3.58 and a 200 day moving average price of $3.63. The stock has a market cap of $141.54 million, a price-to-earnings ratio of -1.70 and a beta of 1.92.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last posted its quarterly earnings data on Tuesday, August 13th. The company reported ($0.52) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.54) by $0.02. On average, sell-side analysts expect that Vigil Neuroscience will post -2.15 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Vigil Neuroscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in shares of Vigil Neuroscience by 11.9% in the first quarter. Vanguard Group Inc. now owns 894,473 shares of the company's stock worth $3,050,000 after acquiring an additional 95,276 shares in the last quarter. Acadian Asset Management LLC acquired a new position in shares of Vigil Neuroscience in the 2nd quarter valued at approximately $26,000. Renaissance Technologies LLC boosted its stake in shares of Vigil Neuroscience by 19.2% during the 2nd quarter. Renaissance Technologies LLC now owns 71,500 shares of the company's stock valued at $286,000 after buying an additional 11,536 shares during the last quarter. Ensign Peak Advisors Inc grew its position in shares of Vigil Neuroscience by 72.8% during the second quarter. Ensign Peak Advisors Inc now owns 395,116 shares of the company's stock worth $1,580,000 after buying an additional 166,442 shares in the last quarter. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new stake in Vigil Neuroscience in the second quarter valued at $87,000. Hedge funds and other institutional investors own 83.64% of the company's stock.

About Vigil Neuroscience

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.